These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 520097

  • 1. Chronochemotherapy: L 1210 leukemia and beyond.
    Halberg F, Nelson W, Cornélissen G, Haus E, Scheving LE, Good RA.
    Chronobiologia; 1979; 6(3):203-11. PubMed ID: 520097
    [Abstract] [Full Text] [Related]

  • 2. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
    Rose WC, Trader MW, Laster WR, Schabel FM.
    Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277
    [No Abstract] [Full Text] [Related]

  • 3. Survival and cure of leukemic mice after circadian optimization of treatment with cyclophosphamide and 1-beta-D-arabinofuranosylcytosine.
    Scheving LE, Burns ER, Pauly JE, Halberg F, Haus E.
    Cancer Res; 1977 Oct; 37(10):3648-55. PubMed ID: 908013
    [Abstract] [Full Text] [Related]

  • 4. Combined chronochemotherapy of L1210 leukemic mice using 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine, methylprednisolone and cis-diamminedichloroplatinum.
    Scheving LE, Burns ER, Halberg F, Pauly JE.
    Chronobiologia; 1980 Oct; 7(1):33-40. PubMed ID: 7192203
    [Abstract] [Full Text] [Related]

  • 5. On methods for testing and achieving cancer chronotherapy.
    Halberg F, Nelson W, Cornelissen G, Haus E, Scheving LE, Good RA.
    Cancer Treat Rep; 1979 Aug; 63(8):1428-30. PubMed ID: 476717
    [No Abstract] [Full Text] [Related]

  • 6. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER, Scheving LE.
    Chronobiologia; 1980 Aug; 7(1):41-51. PubMed ID: 7438892
    [No Abstract] [Full Text] [Related]

  • 7. Circadian bioperiodic response of mice bearing advanced L1210 leukemia to combination therapy with adriamycin and cyclophosphamide.
    Scheving LE, Burns ER, Pauly JE, Halberg F.
    Cancer Res; 1980 May; 40(5):1511-5. PubMed ID: 7370988
    [No Abstract] [Full Text] [Related]

  • 8. Single versus combination chemotherapy of L1210 leukemia.
    Koza I, Balázová E, Ujházy V.
    Neoplasma; 1980 May; 27(6):691-6. PubMed ID: 7254424
    [Abstract] [Full Text] [Related]

  • 9. Combination chemotherapy in sequence for the treatment of L1210 leukemia.
    Roberts D, Hilliard SL.
    Cancer Res; 1978 Aug; 38(8):2317-20. PubMed ID: 667827
    [No Abstract] [Full Text] [Related]

  • 10. Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210.
    Hoffman GS, Kline I, Gang M, Tyrer DD, Goldin A, Mantel N, Venditti JM.
    Cancer Chemother Rep; 1969 Oct; 53(5):265-71. PubMed ID: 5377613
    [No Abstract] [Full Text] [Related]

  • 11. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
    Schmid FA, Hutchison DJ.
    Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
    [No Abstract] [Full Text] [Related]

  • 12. [Modern aspects of using chronopharmacology in hematology. II. Biorhythms in drug effects].
    Berger J, Mikeska J.
    Cas Lek Cesk; 1985 Sep 27; 124(38-39):1220-2. PubMed ID: 4053157
    [No Abstract] [Full Text] [Related]

  • 13. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
    Avery TL, Roberts D.
    Cancer Res; 1977 Mar 27; 37(3):678-83. PubMed ID: 837368
    [Abstract] [Full Text] [Related]

  • 14. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside.
    Buchman VM, Svet-Maoldavsky GJ, Lichinitser MR, Mkheidze DM.
    Biomedicine; 1977 Jul 27; 27(5):179-80. PubMed ID: 922116
    [Abstract] [Full Text] [Related]

  • 15. [Chronobiological aspects of experimental leukemia].
    Ratte J, Haus E, Halberg F, Kühl JF, Shiotsuka R, Najarian JS.
    Union Med Can; 1974 Jul 27; 103(7):1201-7. PubMed ID: 4842174
    [No Abstract] [Full Text] [Related]

  • 16. Circadian dependence of host and tumor responses to cyclophosphamide in mice.
    Cardoso SS, Avery T, Venditti JM, Goldin A.
    Eur J Cancer (1965); 1978 Sep 27; 14(9):949-54. PubMed ID: 710487
    [No Abstract] [Full Text] [Related]

  • 17. Combined therapy of L1210 leukemia with cyclophosphamide and lycurim.
    Stoychkov JN, Milushev AS, Todorov DK.
    Neoplasma; 1980 Sep 27; 27(1):33-6. PubMed ID: 6892839
    [Abstract] [Full Text] [Related]

  • 18. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
    Edelstein M, Vietti T, Valeriote F.
    Cancer Res; 1974 Feb 27; 34(2):293-7. PubMed ID: 4810905
    [No Abstract] [Full Text] [Related]

  • 19. Close reproduction by different laboratories of characteristics of circadian rhythm in 1-beta-D-arabinofuranosylcytosine tolerance by mice.
    Scheving LE, Haus E, Kühl JF, Pauly JE, Halberg F, Cardoso S.
    Cancer Res; 1976 Mar 27; 36(3):1133-7. PubMed ID: 1253172
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX.
    Kline I, Gang M, Tyrer DD, Venditti JM, Artis EW, Goldin A.
    Cancer Chemother Rep 2; 1971 Apr 27; 2(1):65-133. PubMed ID: 5565539
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.